<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736164</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000611981</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RPCI-I-104307</secondary_id>
    <nct_id>NCT00736164</nct_id>
  </id_info>
  <brief_title>Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Clinical Trial of Supplementation of L-Selenomethionine in Patients With Prostate Cancer Prior to Prostatectomy or Brachytherapy (Se Pre-Prostatectomy/Pre-Brachytherapy Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Selenomethionine may slow the growth of prostate cancer. Giving selenomethionine&#xD;
      before surgery or internal radiation therapy may be an effective treatment for prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well selenomethionine works in&#xD;
      treating patients undergoing surgery or internal radiation therapy for stage I or stage II&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the down-regulation of the androgen receptor using tissue samples from&#xD;
           patients with stage I or II prostate cancer treated with selenomethionine for 8-9 weeks&#xD;
           prior to undergoing prostatectomy or brachytherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the down regulation of a number of genes regulated by the androgen receptor&#xD;
           (i.e., prostate-specific antigen, kallikrein 2, cell division cycle 6, and&#xD;
           dehydrocholesterol reductase 24) using tissue samples from these patients.&#xD;
&#xD;
        -  To evaluate the down-regulation of haptic nuclear factor 3-alpha using tissue samples&#xD;
           from these patients.&#xD;
&#xD;
        -  To evaluate whether the thiol methyltransferase phenotype modifies the prostatic&#xD;
           response to short-term selenomethionine supplementation in these patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To use quantitative nuclear morphometry to index cellular abnormality in tissue samples&#xD;
           as measured by nuclear texture (e.g., total optical density, nuclear area, mean nuclear&#xD;
           density, and optical heterogeneity).&#xD;
&#xD;
      OUTLINE: Patients are stratified according to planned treatment (brachytherapy vs&#xD;
      prostatectomy). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral selenomethionine once daily for 8-9 weeks. Patients then&#xD;
           undergo prostatectomy or brachytherapy.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily for 8-9 weeks. Patients then undergo&#xD;
           prostatectomy or brachytherapy.&#xD;
&#xD;
      Blood samples are collected at baseline and on the day of prostatectomy or brachytherapy.&#xD;
      Samples are analyzed for selenium accumulation by atomic absorption spectrophotometry.&#xD;
      Additional blood samples are stored for future analysis of alpha tocopherol, lycopene, and&#xD;
      other vitamin levels, as well as oxidative stress biomarkers. Selenium accumulation is also&#xD;
      evaluated in toenail samples at baseline to assess long-term selenium status. Prostate tissue&#xD;
      samples are obtained during prostatectomy or brachytherapy and analyzed for RNA and&#xD;
      expression of selenium-linked biomarkers (e.g., androgen receptor, prostate-specific antigen,&#xD;
      kallikrein 2, cell division cycle 6, dehydrocholesterol reductase 24, and haptic nuclear&#xD;
      factor 3 alpha) by quantitative reverse transcription (RT)-PCR. Biomarker expression is&#xD;
      compared in both prostatectomy and brachytherapy specimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No accrual&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of androgen receptor message expression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of prostate-specific antigen, kallikrein 2, cell division cycle 6, and dehydrocholesterol reductase 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of haptic nuclear factor 3-alpha</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in thiol methyltransferase phenotype</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral selenomethionine once daily for 8-9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily for 8-9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenomethionine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Diagnosed by sextant or greater biopsy&#xD;
&#xD;
               -  Clinical stage T1a-T2c disease&#xD;
&#xD;
          -  Gleason score &lt; 8&#xD;
&#xD;
          -  Prostate-specific antigen &lt; 20.0 ng/mL&#xD;
&#xD;
          -  Scheduled to undergo prostatectomy or brachytherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy &gt; 5 years&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  Willing to take selenomethionine or placebo for 8-9 weeks immediately prior to&#xD;
             undergoing prostatectomy or brachytherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior hormonal therapy or radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent participation in any other clinical&#xD;
             trial involving a medical, surgical, nutritional, or lifestyle intervention (e.g.,&#xD;
             dietary modification or exercise)&#xD;
&#xD;
          -  No concurrent dietary supplementation with selenium at doses &gt; 60 mcg/day, including&#xD;
             multivitamin supplements&#xD;
&#xD;
          -  No concurrent hormonal therapy, including 5-alpha reductase inhibitors (e.g.,&#xD;
             finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or&#xD;
             ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide&#xD;
             acetate, goserelin acetate, or abarelix)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L. Mohler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <last_update_submitted>February 3, 2012</last_update_submitted>
  <last_update_submitted_qc>February 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <name_title>James L. Mohler</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

